Figure 1 | Scientific Reports

Figure 1

From: MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma

Figure 1

Erlotinib-resistant SCC-R cells show epithelial-to-mesenchymal transition phenotype: (a) Erlotinib-sensitive (SCC-S) and resistant (SCC-R) cells were treated with erlotinib and metabolic activity was evaluated using MTT assay to determine percentage of viable cells. Values were set at 100% for untreated controls. Western blot analysis of (b) EGFR and pEGFR (Y1068) (c) proteins associated with EMT in SCC-S and SCC-R cells. β-actin served as loading control. (d) Migration phenotype of SCC-S and SCC-R cells as seen at 0 hr and 12 hr post-scratch wounding.

Back to article page